$BIAF October marked our highest monthly CyPath® Lung testing volume representing a 29% increase compared with October 2025.
Both established and newly ordering physicians are providing a new measure of utilization following the close of Q3.
For our business, expanding adoption means reaching new physicians while increasing use of our test among those already ordering CyPath Lung. October’s record reflects activity across both groups.
We’re supporting these efforts through increased marketing, an expanded sales team, direct physician engagement and our relationships with patient advocacy organizations to strengthen our connections within the lung cancer community.
$BIAF At bioAffinity Technologies, we’re building our business around a clear clinical need: helping physicians determine next steps in care through noninvasive testing for patients at risk for lung cancer.
This official Investor Relations channel is here to keep you informed about our business, science and progress. We want to hear your questions and perspectives. Your voice matters.